Ortego-Jurado, MiguelCallejas-Rubio, José-LuisRíos-Fernández, RaquelGonzález-Moreno, JuanGonzález Ramírez, Amanda RocíoGonzález-Gay, Miguel AOrtego-Centeno, Norberto2016-12-092016-12-092015Ortego-Jurado M, Callejas-Rubio JL, Ríos-Fernández R, González-Moreno J, González Ramírez AR, González-Gay MA, et al. Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study. J Osteoporos; 2015:7294512042-0064http://hdl.handle.net/10668/2565Journal Article;Glucocorticoids (GCs) are the cornerstone of the therapy in many autoimmune and inflammatory diseases. However, it is well known that their use is a double edged sword, as their beneficial effects are associated almost universally with unwanted effects, as, for example glucocorticoid-induced osteoporosis (GIO). Over the last years, several clinical practice guidelines emphasize the need of preventing bone mass loss and reduce the incidence of fractures associated with GC use. Calcium and vitamin D supplementation, as adjunctive therapy, are included in all the practice guidelines. However, no standard vitamin D dose has been established. Several studies with postmenopausal women show that maintaining the levels above 30-33 ng/mL help improve the response to bisphosphonates. It is unknown if the response is the same in GIO, but in the clinical practice the levels are maintained at around the same values. In this study we demonstrate that patients with autoimmune diseases, undergoing glucocorticoid therapy, often present suboptimal 25(OH)D levels. Patients with higher body mass index and those receiving higher doses of glucocorticoids are at increased risk of having lower levels of 25(OH)D. In these patients, calcidiol supplementations are more effective than cholecalciferol to reach adequate 25(OH)D levels.enEnfermedades autoinmunesÍndice de masa corporalCalcifediolCalcio en la dietaColecalciferolDifosfonatosFemeninoFracturas óseasGlucocorticoidesHumanosIncidenciaPosmenopausiaVitamina DVitaminasMedical Subject Headings::Diseases::Immune System Diseases::Autoimmune DiseasesMedical Subject Headings::Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Mass IndexMedical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Cholestanes::Cholestenes::Cholecalciferol::Hydroxycholecalciferols::CalcifediolMedical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Calcium Compounds::Calcium, DietaryMedical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Cholestanes::Cholestenes::CholecalciferolMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Organophosphorus Compounds::DiphosphonatesMedical Subject Headings::Check Tags::FemaleMedical Subject Headings::Diseases::Wounds and Injuries::Fractures, BoneMedical Subject Headings::Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones::GlucocorticoidsMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::IncidenceMedical Subject Headings::Diseases::Musculoskeletal Diseases::Bone Diseases::Bone Diseases, Metabolic::OsteoporosisMedical Subject Headings::Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause::PostmenopauseMedical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Secosteroids::Vitamin DMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Growth Substances::Micronutrients::Vitaminsresearch article26124976open access10.1155/2015/7294512090-8059PMC4466436